Thromboprophylaxis in COVID-19 - Rationale and considerations.
Adv Biol Regul
; 81: 100819, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1322183
ABSTRACT
The Corona Virus Disease-2019 (COVID-19) pandemic is associated with a very high incidence of thrombotic complications. The exact mechanisms for this excess risk for clots have not been elucidated although one of the often-quoted pathophysiological entity is immunothrombosis. Recognition of thrombotic complications early on in this pandemic led to an over-explosion of studies which looked at the benefits of anticoagulation to mitigate this risk. In this review, we examine the rationale for thromboprophylaxis in COVID-19 with particular reference to dosing and discuss what may guide the decision-making process to consider anticoagulation. In addition, we explore the rationale for thrombosis prevention measures in special populations including outpatient setting, pregnant females, children, those with high body mass index and those on extracorporeal membrane oxygenation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombosis
/
Extracorporeal Membrane Oxygenation
/
SARS-CoV-2
/
COVID-19
/
Anticoagulants
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Adv Biol Regul
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS